Avalyn Pharma (NASDAQ:AVLN) Reaches New 52-Week Low – Here’s Why

Avalyn Pharma Inc. (NASDAQ:AVLN) reached a new 52-week low on Tuesday. The company traded as low as $22.24 and last traded at $23.57, with a volume of 9,188 shares. The stock had previously closed at $23.33.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AVLN. Wall Street Zen downgraded Avalyn Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Weiss Ratings started coverage on shares of Avalyn Pharma in a research report on Thursday, August 13th. They issued a “sell (d+)” rating on the stock. Raymond James Financial started coverage on shares of Avalyn Pharma in a research note on Friday, October 2nd. They set an “outperform” rating and a $60.00 target price for the company. Finally, Morgan Stanley lifted their price target on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $60.00.

Avalyn Pharma Price Performance

The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. The business’s fifty day moving average is $31.82.

Avalyn Pharma (NASDAQ:AVLN) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.05. Equities analysts expect that Avalyn Pharma Inc. will post -3.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Avalyn Pharma

Several hedge funds have recently bought and sold shares of AVLN. State Street Corp acquired a new position in Avalyn Pharma during the 2nd quarter worth about $10,501,000. Braidwell LP acquired a new position in Avalyn Pharma in the 2nd quarter valued at about $26,382,000. Montanova Capital LLC acquired a new position in Avalyn Pharma in the 2nd quarter valued at about $82,402,000. Finally, Bank of New York Mellon Corp purchased a new stake in Avalyn Pharma during the second quarter worth about $1,321,000.

Avalyn Pharma Company Profile

Avalyn Pharma, Inc (NASDAQ: AVLN) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with pulmonary fibrosis and other serious respiratory diseases. The company’s research is aimed at delivering established antifibrotic medicines directly to the lungs, with the potential to improve treatment effectiveness while reducing systemic exposure and associated side effects.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.